Expert Opinion on Pharmacotherapy最新文献_第2页

Use of glucagon-like polypeptide 2 analogs for intestinal failure. 使用胰高血糖素样多肽 2 类似物治疗肠功能衰竭。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-26 DOI: 10.1080/14656566.2024.2431291

Monique L Goldschmidt, Stephanie Oliveira, Crystal Slaughter, Samuel A Kocoshis

{"title":"Use of glucagon-like polypeptide 2 analogs for intestinal failure.","authors":"Monique L Goldschmidt, Stephanie Oliveira, Crystal Slaughter, Samuel A Kocoshis","doi":"10.1080/14656566.2024.2431291","DOIUrl":"https://doi.org/10.1080/14656566.2024.2431291","url":null,"abstract":"Introduction: Over a half century ago, a component of glucagon was found to have potent gastrointestinal effects. Shortly after proglucagon was sequenced, its component peptides were characterized, and glucagon-like polypeptide-2 (GLP-2) was noted to have the most potent intestinotrophic properties improving fluid and electrolyte balance in experimental animals and humans.Areas covered: Glucagon-like polypeptide-1 (GLP-1) slows small intestinal motility more effectively, but its intestinotrophic properties are weaker. GLP-2's properties prompted study of its effects upon function of the surgically foreshortened small intestine, but its short half-life limited its usefulness, but the subsequent discovery that substitution of glycine for alanine at the second position of the molecule's N-terminus could lengthen its half-life to 2.5 hours, established efficacy in short bowel management with a single daily subcutaneous injection. Both adult and pediatric studies have shown reduced parenteral nutrition requirements and establishment of enteral autonomy for some patients. More recently, ultralong acting GLP-2 analogs with half-lives of 70-80 hours can improve gastrointestinal function in surgically foreshortened bowel with only one injection every three to seven days.Expert opinion: Future research is likely to focus upon the potential complementary role of GLP-1 and GLP-2 in treating short bowel syndrome.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-6"},"PeriodicalIF":2.5,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New pharmacotherapeutic strategies for drug-resistant candida infections: a review. 耐药性念珠菌感染的新药物治疗策略：综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-25 DOI: 10.1080/14656566.2024.2433605

Jesse Raposa, Jose A Vazquez

{"title":"New pharmacotherapeutic strategies for drug-resistant candida infections: a review.","authors":"Jesse Raposa, Jose A Vazquez","doi":"10.1080/14656566.2024.2433605","DOIUrl":"https://doi.org/10.1080/14656566.2024.2433605","url":null,"abstract":"Introduction: Candida species produce a wide array of infections ranging from mucocutaneous to systemic infections. Candida albicans remains the most common species identified, however the non-albicans Candida species have continued to increase as the diagnosis and therapeutic regimens have progressed.Areas covered: This review with discuss the various Candida species, especially the non-albicans species, some of the important mechanisms of resistance, and newer in vitro and clinical studies describing the recent and novel antifungal options such as rezafungin, ibrexafungerp, and oteseconazole, along with a novel antifungal, fosmanogepix.Expert opinion: Initial antifungal therapy is frequently obsolete due to the expansion of antifungal resistance. This is especially true with C. glabrata, C. krusei, and most recently with C. auris. The newer and novel antifungals discussed here will add valuable tools to our antifungal armamentarium to be able to appropriately and adequately treat and manage these difficult infections. Each of the antifungals has unique and novel properties that will expand the arsenal useful to treat these fungal infections in the years to come.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU. 改善重症监护病房肺炎抗菌治疗的药代动力学/药效学结果。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-25 DOI: 10.1080/14656566.2024.2432478

Michael Thy, Sophie Magréault, Jean-Ralph Zahar, Vincent Jullien, Jean-François Timsit

{"title":"Improving pharmacokinetic/pharmacodynamic outcomes of antimicrobial therapy for pneumonia in the ICU.","authors":"Michael Thy, Sophie Magréault, Jean-Ralph Zahar, Vincent Jullien, Jean-François Timsit","doi":"10.1080/14656566.2024.2432478","DOIUrl":"https://doi.org/10.1080/14656566.2024.2432478","url":null,"abstract":"Introduction: Pneumonia remains a significant global health challenge due to its high prevalence and mortality rate, and challenging treatment. This review explores the best strategies to optimize the antibiotic therapy for pneumonia in critically ill patients, focusing on pharmacokinetics, pharmacodynamics, and therapeutic data.Areas covered: A review of scientific publications on severe pneumonia highlights the challenges of optimizing antibiotic use to improve lung diffusion, bacterial killing, and achieving PK/PD targets, emphasizing the need to understand microbiological epidemiology and MIC breakpoints. Key strategies like nebulization, therapeutic drug monitoring, and emerging technologies such as ELF TDM and nanomaterial-based drug delivery systems are essential for optimizing PK/PD outcomes and addressing antimicrobial resistance.Expert opinion: Improving our understanding of pulmonary pharmacokinetics and optimizing their tissue diffusion are instrumental for achieving precision antibiotic therapy for severe pneumonia. By addressing current limitations and embracing interdisciplinary collaboration, we can pave the way for more efficient personalized approaches in infectious diseases management.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142715828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine. 胆道癌症的系统治疗方法：多向精准医疗时代的综述。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-24 DOI: 10.1080/14656566.2024.2432488

Cha Len Lee, Anna Saborowski, Arndt Vogel

{"title":"Systemic approaches in biliary tract cancers: a review in the era of multidirectional precision medicine.","authors":"Cha Len Lee, Anna Saborowski, Arndt Vogel","doi":"10.1080/14656566.2024.2432488","DOIUrl":"10.1080/14656566.2024.2432488","url":null,"abstract":"Introduction: Despite a rising incidence, biliary tract cancers (BTCs) are still considered a rare tumor entity. The disease's subtle clinical presentation and lack of effective early detection strategies often lead to a diagnosis at an advanced or unresectable stage, where curative options are limited.Areas covered: This review provides an overview of current systemic therapies and emerging novel approaches for BTC. For decades, the combination of gemcitabine with cisplatin (GemCis) has been the standard of care for palliative treatment. However, since 2020, the diagnostic and therapeutic landscape for BTC has evolved considerably, not only in the first-line setting but also beyond, driven by the development of clinical trials exploring immunotherapy and molecularly targeted agents. Due to the high frequency of targetable genetic alterations in BTC patients, there is a growing emphasis on obtaining tissue or liquid biopsy samples to identify markers like microsatellite instability and other actionable oncogenic driver genes.Expert opinion: Early initiation of systemic therapies in combination with multimodal approaches is essential for maximizing survival outcomes in patients with BTC.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":2.5,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to the editor - 'Olezarsen, a liver-directed APOC3 ASO therapy for hypertriglyceridemia'. 致编辑的信--"olezarsen，一种治疗高甘油三酯血症的肝脏导向 APOC3 ASO疗法"。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-21 DOI: 10.1080/14656566.2024.2432487

Melvin Khee Shing Leow

引用次数: 0

Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors. 治疗孤儿、标签外、儿科药物开发：为未成年人提供合理的药物治疗。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-14 DOI: 10.1080/14656566.2024.2426678

Klaus Rose, Jane M Grant-Kels, Pasquale Striano

{"title":"Therapeutic orphans, off-label, pediatric drug development: towards reasonable pharmacotherapy for minors.","authors":"Klaus Rose, Jane M Grant-Kels, Pasquale Striano","doi":"10.1080/14656566.2024.2426678","DOIUrl":"https://doi.org/10.1080/14656566.2024.2426678","url":null,"abstract":"Introduction: The concept that children are therapeutic orphans emerged in the 1960s, triggering eventually worldwide legislation to facilitate pediatric studies, called 'Pediatric Drug Development (PDD).' However, PDD's true aim is not better medicines for children but labels in minors; minors are not another species.Areas covered: Absorption, distribution, metabolism, and excretion (ADME) differ in preterm newborns, but babies mature. With the exception of neonatology, the justifications for clinical, pharmacokinetic, and safety studies were and are exaggerated.Expert opinion: PDD reflects an artificial regulatory challenge, reflecting mankind's transition into a world of effective new drugs compared to previous millennia when only materials taken from nature were available. Minors need dose assessment and proof of safety; there is a tendency to exaggerate the scope of pharmacokinetic and safety studies before and after the eighteenth birthday, potentially motivated not by industry's greed, but by researchers' desire for funding and regulatory authorities' desire for recognition, specifically as since 2007 the European Medicines Agency (EMA) augmented and expanded PDD: a new type of conflict of interest in medicines' administration and mainstream medical science.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.5,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment. 研究尼罗加司他对需要系统治疗的进展期类脂膜瘤成人患者的疗效。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI: 10.1080/14656566.2024.2418416

Fernando Campos, Bernd Kasper

{"title":"Examining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.","authors":"Fernando Campos, Bernd Kasper","doi":"10.1080/14656566.2024.2418416","DOIUrl":"10.1080/14656566.2024.2418416","url":null,"abstract":"Introduction: Desmoid tumor (DT) is a rare, locally aggressive, mesenchymal neoplasm that can arise at any site in the body. Medical therapies play a major role for DT's patients requiring treatment. A novel systemic approach has recently emerged with Nirogacestat, a γ-secretase inhibitor targeting the NOTCH signaling pathway.Areas covered: Nirogacestat is the first drug in its class to receive approval from the Food and Drug Administration (FDA) and is the first FDA-approved treatment specifically for DTs. We reviewed the data leading to its discovery, including its mechanism of action, pharmacological properties, clinical efficacy, and its positioning within the current treatment armamentarium for DTs.Expert opinion: High-quality evidence for systemic therapies in the management of DTs remains an unmet need. Nirogacestat now joins sorafenib as the only drugs with efficacy in DTs demonstrated by randomized phase 3 studies. Currently, there are no comparative trials of the available systemic therapies. Therefore, physicians should consider factors such as drug accessibility, cost, toxicity profile, comorbidities, and patient preferences when selecting treatment. Long-term efficacy and safety data will be essential for evaluating the duration of treatment response and monitoring late-onset side effects of Nirogacestat.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2115-2124"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological and non-pharmacological management of sleep disturbances in Parkinson's disease: if when and how. 帕金森病患者睡眠障碍的药物和非药物治疗：如果、何时以及如何治疗。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-11-13 DOI: 10.1080/14656566.2024.2422004

Cristian Falup-Pecurariu, Maria-Lucia Muntean, Larisa Ungureanu, Iulia Murasan, Karolina Popławska-Domaszewicz, Kallol Ray Chaudhuri, Stefania Diaconu

{"title":"Pharmacological and non-pharmacological management of sleep disturbances in Parkinson's disease: if when and how.","authors":"Cristian Falup-Pecurariu, Maria-Lucia Muntean, Larisa Ungureanu, Iulia Murasan, Karolina Popławska-Domaszewicz, Kallol Ray Chaudhuri, Stefania Diaconu","doi":"10.1080/14656566.2024.2422004","DOIUrl":"10.1080/14656566.2024.2422004","url":null,"abstract":"Introduction: Sleep dysfunction occurs in various forms and is a bothersome and intrusive non-motor symptom of Parkinson's disease (PD). Frequently undiagnosed, their poor management can have a great impact on the quality of life of PD patients and their caregivers.Areas covered: This article covers the safety and efficacy of pharmacological strategies for the management of the most frequent sleep disturbances in Parkinson's disease. Non-pharmacological aspects are also discussed, but these are not the main focus. Literature searches using electronic databases (Medline, Cochrane Library) and systematic checking of references from review articles/other reports were performed.Expert opinion: Melatonin and clonazepam are the most commonly used therapies for the management of REM sleep behavior disorder (RBD). The most used pharmacological wake-promoting agents in the treatment of excessive daytime sleepiness (EDS) are modafinil and caffeine. Poor nocturnal sleep quality is usually linked to EDS, thus proper sleep hygiene is recommended. As nocturnal motor symptoms are commonly associated with sleep fragmentation and early morning off, optimization of dopaminergic treatment during nighttime is highly recommended for the proper management of insomnia. Further interventions include eszopiclone and melatonin for the management of insomnia. Therapeutic options for restless legs syndrome (RLS) include calcium channel alpha-2-delta ligands and low-dose dopamine agonists (DA). Further confirmatory evidence is needed before the general recommendation of these treatments.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2135-2149"},"PeriodicalIF":2.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome. 多囊卵巢综合征患者不孕症药物治疗策略的最新进展。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-20 DOI: 10.1080/14656566.2024.2418985

Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa

{"title":"Recent developments in drug treatment strategies for infertility in patients with polycystic ovary syndrome.","authors":"Stefano Palomba, Marianna Molinaro, Alice Ingargiola, Antonio Aversa","doi":"10.1080/14656566.2024.2418985","DOIUrl":"10.1080/14656566.2024.2418985","url":null,"abstract":"Introduction: Infertility related to polycystic ovary syndrome (PCOS) represents a significant challenge for women of reproductive age. Over the last few years, evidence-based medicine has driven new approaches for treating infertility in patients with PCOS, changing rapidly and deeply the clinical practice.Areas covered: The authors provide an in-depth examination of recent developments in drug treatment strategies that have impacted the clinical practice and changed the previous approach to infertility in patients with PCOS.Expert opinion: The authors identify four primary areas of interest that have impacted clinical practice in the last few years. Specifically, they discuss the current role of metformin administration in women with PCOS and infertility, the choice for using clomiphene citrate or letrozole as first-line treatment for ovulation induction, the use of new gonadotropin formulations for in vitro fertilization (IVF) program, and the elective embryo transfer in IVF cycles as golden standard treatment for patients with PCOS at high-risk for ovarian hyperstimulation syndrome.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2191-2202"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An update on the pharmacological management of acne vulgaris: the state of the art. 药物治疗寻常痤疮的最新进展：最新技术。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-20 DOI: 10.1080/14656566.2024.2418986

Isabel Cristina Valente Duarte de Sousa

{"title":"An update on the pharmacological management of acne vulgaris: the state of the art.","authors":"Isabel Cristina Valente Duarte de Sousa","doi":"10.1080/14656566.2024.2418986","DOIUrl":"10.1080/14656566.2024.2418986","url":null,"abstract":"Introduction: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit that affects approximately 9.4% of the global population. Current treatment strategies aim to target as many pathogenic factors involved in the appearance of acne lesions and are centered on a systematic treatment escalation based on disease severity, extension, and treatment response, starting with topical treatments for mild cases and progressing over to systemic therapies in more severe cases. A literature search, which included clinical guidelines, clinical studies, and review articles on acne treatment and maintenance, was conducted to review the pharmacological approaches currently available to treat this disease.Areas covered: Topical therapies such as topical retinoids, benzoyl peroxide, azelaic acid, salicylic acid, topical antibiotics, and clascoterone, as well as systemic treatments such as oral antibiotics and isotretinoin are discussed in detail. Combined oral contraceptives and spironolactone will not be discussed in this article.Expert opinion: There is a need for a blockbuster acne drug that simultaneously targets the four main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2177-2190"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0